dilauroyl phosphatidylcholine

Dilauroyl phosphatidylcholine (DLPC) is a synthetic or naturally occurring phospholipid (specifically a phosphatidylcholine with two saturated 12-carbon lauroyl chains) that acts as a selective agonist of the orphan nuclear receptor liver receptor homolog-1 (LRH-1, also known as NR5A2). Discovered to have potent metabolic and anti-inflammatory properties, DLPC activates LRH-1 to regulate bile acid biosynthesis, improve glucose homeostasis, and reduce hepatic steatosis. It is being developed by academic institutions, including Baylor College of Medicine and the University of Colorado, for the treatment of metabolic disorders such as prediabetes, as well as cholestatic liver diseases including parenteral nutrition-associated cholestasis (PNAC) and primary sclerosing cholangitis (PSC). DLPC exerts its therapeutic effects by promoting the polarization of restorative, regulatory macrophages (Mregs) and upregulating anti-inflammatory pathways such as STAT6 and ERK signaling.

Other names

1,2-dilauroyl-sn-glycero-3-phosphatidylcholine1,2-dilauroyl-sn-glycero-3-phosphocholine1,2-dilauroylphosphatidylcholine1,2-DLPCDLPCdilauroyl lecithindilauroylphosphatidylcholinedilaurylphosphatidylcholine